Marquis Labs, LLC

Marquis Labs, LLC was paid $4.84M by Medicaid between Jan 2018 and Nov 2024, across 98 billing codes. Its largest line is U0004, 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r — 61% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in Oklahoma

Rank by total paid#8 of 46

Median peer was paid$248K

This provider vs. median19×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	5,329	$65K
2019	12,545	$39K
2020	10,491	$156K
2021	21,211	$416K
2022	81,264	$2.29M
2023	53,462	$1.80M
2024incomplete	2,330	$68K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0004	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r	61%	55,622	35,815	$2.96M
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	17%	52,668	34,626	$804K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	14%	47,423	30,513	$696K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	2.2%	2,502	996	$106K
87637	Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV	<1%	736	649	$42K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	<1%	697	629	$25K
U0002	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc	<1%	454	406	$18K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	<1%	739	446	$14K
87481		<1%	309	213	$11K
83970		<1%	640	588	$9K
80053	Comprehensive metabolic panel	<1%	1,369	1,242	$9K
80061	Lipid panel	<1%	1,531	1,381	$9K

86 more codes

84481		<1%	1,128	$9K
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	<1%	546	$8K
84443	Thyroid stimulating hormone (TSH)	<1%	1,145	$8K
10005		<1%	66	$7K
82670		<1%	636	$7K
82172		<1%	815	$6K
84403		<1%	654	$6K
84439		<1%	1,243	$5K
82627		<1%	586	$5K
83001		<1%	633	$4K
83002		<1%	633	$4K
87486		<1%	227	$4K
83036	Hemoglobin; glycosylated (A1C)	<1%	1,023	$4K
86800		<1%	648	$3K
82728		<1%	655	$3K
84270		<1%	345	$3K
86376		<1%	649	$3K
82533		<1%	570	$3K
87581		<1%	84	$3K
80050	General health panel	<1%	291	$3K
86141		<1%	659	$3K
83525		<1%	650	$2K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	1,007	$2K
83695		<1%	641	$2K
82746		<1%	538	$2K
83550		<1%	846	$2K
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	<1%	432	$2K
84402		<1%	188	$2K
84144		<1%	234	$2K
83880		<1%	54	$2K
83540		<1%	695	$1K
83735		<1%	402	$1K
87541		<1%	143	$1K
82607		<1%	233	$1K
87640		<1%	105	$1K
87651	Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe	<1%	101	$1K
87653		<1%	105	$1K
82530		<1%	70	$871.68
10004		<1%	18	$759.55
84153		<1%	48	$677.72
82747		<1%	70	$598.01
83615		<1%	126	$428.48
87150		<1%	29	$396.36
G0103	Prostate cancer screening; prostate specific antigen test (psa)	<1%	115	$312.91
81000		<1%	205	$251.64
85651		<1%	61	$206.12
85652		<1%	106	$105.44
82043		<1%	22	$91.86
82570		<1%	22	$82.44
82550		<1%	31	$74.48
80346		<1%	42	$64.66
80336		<1%	38	$63.77
80348		<1%	37	$59.35
80342		<1%	42	$56.17
80048	Basic metabolic panel (calcium, ionized)	<1%	41	$54.88
80325		<1%	43	$50.76
80361		<1%	42	$41.98
80356		<1%	42	$41.98
80372		<1%	38	$37.09
80373		<1%	40	$37.09
80334		<1%	38	$34.54
80369		<1%	41	$34.09
80358		<1%	42	$31.78
80364		<1%	23	$31.78
80365		<1%	41	$31.78
80333		<1%	42	$29.23
80368		<1%	39	$28.27
80366		<1%	40	$28.27
84436		<1%	12	$28.21
80355		<1%	43	$27.09
80353		<1%	39	$24.74
80359		<1%	43	$22.96
80371		<1%	39	$22.96
80360		<1%	38	$22.96
83992		<1%	43	$19.92
80329		<1%	39	$16.90
81003		<1%	127	$16.41
80324		0%	39	$0.00
82040		0%	64	$0.00
87389	Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies	0%	17	$0.00
80363		0%	20	$0.00
80332		0%	38	$0.00
84681		0%	21	$0.00
80074		0%	17	$0.00
85014		0%	41	$0.00
80362		0%	18	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialBROOKS, SAM (PARTNER)